Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification

Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification

Bibliographic Details
Main Authors:	Zhi-Mei Zhao, Song-Ping Wang, Lei Sun, You-Xin Ji, Pei-Fang Wei
Format:	Article
Language:	English
Published:	Wolters Kluwer 2021-02-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000001184

Similar Items

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
by: Katsuhiro Yoshimura, MD, et al.
Published: (2017-01-01)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
by: Balázs Jóri, et al.
Published: (2023-09-01)

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
by: Waleed Kian, et al.
Published: (2023-02-01)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
by: Miriam Blasi, et al.
Published: (2021-03-01)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
by: Zhu VW, et al.
Published: (2019-03-01)

TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
by: Caihua Xu, MD, et al.
Published: (2020-06-01)

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
by: Shigeki Nanjo, et al.
Published: (2013-01-01)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
by: Xiaomeng Wang, et al.
Published: (2021-07-01)

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo <i>MET</i> Amplification in Patients with Metastatic <i>EGFR</i>-Mutated NSCLC
by: Edyta M. Urbanska, et al.
Published: (2023-08-01)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
by: Kaiwen Wang, PharmD, et al.
Published: (2023-08-01)

Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]
by: Tianyao Lei, et al.
Published: (2023-10-01)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
by: Philippe Rochigneux, et al.
Published: (2018-11-01)

Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
by: Oliver Gautschi, MD, et al.
Published: (2021-04-01)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
by: Shinkichi Takamori, et al.
Published: (2022-10-01)

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
by: Molly S.C. Li, M.B.B.S., et al.
Published: (2024-04-01)

A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib
by: Mehmet Artaç, et al.
Published: (2018-08-01)

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
by: Albina Kibirova, et al.
Published: (2019-10-01)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
by: Lin-Peng Zheng, et al.
Published: (2018-11-01)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
by: Kazuto Nishio, MD, PhD, et al.
Published: (2021-06-01)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
by: Ji Ruan
Published: (2021-01-01)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
by: Richard J. Honeywell, et al.
Published: (2020-11-01)

Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review
by: Guoxin Hou, et al.
Published: (2019-06-01)

Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
by: Alejandro Ríos-Hoyo, et al.
Published: (2022-04-01)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
by: Molly Wilgucki, DO, et al.
Published: (2022-10-01)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
by: Fei-fei Gu, et al.
Published: (2016-08-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

Primary resistance to osimertinib despite acquired T790M
by: Ling‐Kai Chang, et al.
Published: (2020-03-01)

Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion
by: Su-Su Dong, et al.
Published: (2024-04-01)

Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
by: Elisa Bertoli, et al.
Published: (2022-06-01)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
by: Kang Miao, et al.
Published: (2023-05-01)

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
by: Norma A. Palma, et al.
Published: (2014-07-01)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
by: T. L. Peters, et al.
Published: (2021-10-01)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
by: Yan Chen, et al.
Published: (2022-06-01)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion
by: Lanzi Ou, et al.
Published: (2022-07-01)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
by: Rui-Lian Chen, et al.
Published: (2018-11-01)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
by: Jiyun Lee, et al.
Published: (2022-12-01)

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
by: Ismail M. Meraz, et al.
Published: (2023-05-01)

Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report
by: Yangjun Gu, et al.
Published: (2023-08-01)